MedTrace Logo

LifeVest Post-CABG Registry

NCT01448005 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 69

Last updated 2017-12-06

No results posted yet for this study

Summary

This is a multi-center prospective registry of patients with an ejection fraction (EF) ≤ 35% following coronary artery bypass graft (CABG) surgery in order to test the hypothesis that wearable defibrillators (WD) will decrease overall mortality after discharge by decreasing arrhythmic death in this select population with high risk for sudden cardiac death (SCD). This is a pilot project to determine the feasibility of a larger-scale study.

Conditions

  • Sudden Cardiac Death
  • Ventricular Fibrillation
  • Ventricular Tachycardia
  • Ventricular Dysfunction
  • Myocardial Ischemia

Interventions

DEVICE

wearable defibrillator (LifeVest)

A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.

Sponsors & Collaborators

  • Zoll Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Steven J Szymkiewicz, MD · Zoll Medical Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2014-09-30
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448005 on ClinicalTrials.gov